EX-4.22
Published on
Exhibit 4.22
Certain information identified by [***] has been omitted from this exhibit because it is both not material and is the type that the registrant treats as confidential.
LICENSE AGREEMENT
This License Agreement (“Agreement”) is entered into and made effective as of 11 June, 2024 (the “Effective Date”), by and between The Council of the Queensland Institute of Medical Research ABN 31 411 813 344 (“Institute”), a not-for-profit institute organized and existing under the laws of the state of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia; and Kazia Therapeutics Limited ABN 37 063 259 754 (“Kazia”), having its principal offices at L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia. Institute and Kazia are each known as a “Party” herein, and are collectively known as the “Parties.”
WHEREAS Institute is the owner of certain intellectual property rights in relation to combination therapies consisting of (a) PI3K inhibitor drugs, on the one hand, and (b) one or more immunotherapy or PARP inhibitor drugs (“PI3K Combination”);
WHEREAS, Kazia Controls (as defined below) certain intellectual property rights in relation to the PI3K inhibitor drug generically known as paxalisib (formerly known as GDC-0084) and is engaged in the development paxalisib both as a monotherapy and in combination with one or more other drugs;
WHEREAS, Kazia wishes to obtain an exclusive license to certain intellectual property rights owned or controlled by Institute in relation to the PI3K Combination necessary or useful for the development, manufacture and commercialization of Licensed Products (as defined below), and Kazia is committed to developing and commercializing such Licensed Products, on the terms and conditions of this Agreement;
WHEREAS, Institute is willing to grant such a license to Kazia, on the terms and conditions of this Agreement; and
NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt of which is hereby acknowledged, Institute and Kazia agree as follows:
1. DEFINITIONS
1.1. “Affiliate” means, with respect to a Party, any entity that directly or indirectly owns or controls, is owned or controlled by, or is under common ownership or control of that Party. With respect to an entity, the terms “own” and “control” (including, with correlative meaning, the terms “owned”, “controlled by” and “under common ownership or control”) shall mean (a) direct or indirect ownership of at least 50% of the equity interests of that entity; [(b) the power to direct the management and policies of that entity;] (c) the power to appoint or remove a majority of the board of directors or equivalent governance body of that entity; or (d) the right to receive 50% or more of the profits or earnings of that entity. The term “entity” includes without limitation any individual, corporation, partnership, limited liability company, or other organization of any kind.
Page 1
1.2. “Applicable Law” means any applicable federal, state, local or foreign law, statute, ordinance, principle of common law, or any rule, regulation, standard, judgment, order, writ, injunction, decree, arbitration award, agency requirement, license or permit of any governmental authority, or of any national securities exchange or securities listing organisation on which a Party’s or its Affiliates’ stock is publicly traded.
1.3. “Biosimilar Product” means, with respect to a Licensed Product in a country, any product sold by a Third Party (without a license, authorization, or other grant of rights by Kazia) that (a) is subject to a license for administration to humans under Section 351(a) or 351(k) of the U.S. Public Health Services Act (“PHSA”) and (i) contains an active ingredient that is the same as the active ingredient of such Licensed Product or (ii) is “biosimilar” (as defined in Section 351(i)(2) of the PHSA) or “interchangeable” (as defined in Section 351(i)(3) of the PHSA) to such Licensed Product (or otherwise bioequivalent, biosimilar, interchangeable, or the like, in each case, to such Licensed Product under analogous laws), (b) has been licensed as a similar biological medicinal product by EMA pursuant to Directive 2001/83/EC, as may be amended, or any subsequent or superseding law, statute or regulation, or (c) has otherwise received Regulatory Approval as a generic, biosimilar, bioequivalent, or interchangeable product from another applicable Regulatory Authority in such country, including by referencing Regulatory Approvals (or data therein) of such Licensed Product.
1.4. ”Business Day” means any day other than a Saturday, Sunday or public holiday in Australia.
1.5. “Collaborative Research Agreement” means the Collaborative Research Agreement the Parties may enter into in respect to one or more PI3K Combinations.
1.6. “Commercially Reasonable Efforts” means, with respect to the efforts to be expended by a Party with respect to any objective, activity or decision to be undertaken under this Agreement, those efforts that a company developing technology within the bio-pharmaceutical industry of comparable size and resources would reasonably use to accomplish such objective, activity or decision under similar circumstances, and specifically means the carrying out of development activities using efforts that a company developing technology within the bio- pharmaceutical industry of comparable size and resources would reasonably devote to a product at a similar stage in its development or commercial product life and of similar market potential, taking into consideration, among other factors, Third Party costs and expenses, including the royalties, milestone and other payments payable to Third Party licensors of patent or other intellectual property rights, and the pricing and reimbursement relating to the product, based on conditions then prevailing, efficacy, safety, approved labeling, the competitiveness of alternative products sold by Third Parties in the marketplace, the patent and other proprietary position of the product, and the likelihood of Regulatory Approval given the regulatory structure involved and the Party’s remaining product portfolio and other commercial imperatives. For clarity, the efforts of Kazia’s Affiliates, Sublicensee’s and Subcontractors will be considered the efforts of Kazia, and Commercially Reasonable Efforts will not mean that a Party guarantees that it will actually accomplish the applicable task or objective.
Page 2
1.7. “Confidential Information” of a Party means (A) all information disclosed by or on behalf of such Party or any of its Affiliates to the other Party or any of its Affiliates under this Agreement regarding the intellectual property licensed and/or created hereunder, the terms of this Agreement (which shall be Confidential Information of each Party), the performance of such Party hereunder, and in the case of Kazia its business and technical information relating to the research, development and commercialization of pharmaceutical products pertaining to human disorders and diseases, including Know-How and data and/or technical information developed by such Party under a Research Plan and in the case of Kazia, by Kazia outside of a Research Plan and any other information that is or should reasonably be regarded as confidential to the Party to whom it belongs or relates, in each case that is disclosed either in writing or other medium, orally or in any other form, and (B) any information disclosed by such Party under that certain Confidentiality Agreement between the Parties dated July 1, 2020 (the “Confidentiality Agreement”), in each case (A) and (B) other than information that (a) was known or used by the receiving Party prior to its date of disclosure to the receiving Party as demonstrated by competent written records, except to the extent disclosed in connection with a written agreement of the Parties providing for confidentiality; (b) either before or after the date of the disclosure to the receiving Party, is lawfully disclosed to the receiving Party on a non-confidential basis by sources other than the disclosing Party rightfully in possession of the information; (c) either before or after the date of the disclosure to the receiving Party, is published or otherwise part of the public domain through no fault or omission on the part of the receiving Party; or (d) is independently developed by or for the receiving Party without access to or use of the disclosing Party’s Confidential Information, as can be demonstrated by competent written records.
1.8. “Control” means, with respect to any intellectual property right, that a Party owns or has a license (other than a license granted to such Party under this Agreement) to such intellectual property right and has the ability to grant to the other Party a license, sublicense or other right thereto without violating the terms of any then-existing agreement or other legally enforceable arrangement with any Third Party.
1.9. “Dollar”, “dollar”, or “$” means the legal tender of the United States.
1.10. “Effective Date” means the date set forth in the preamble of this Agreement.
1.11. “EMA” means the European Medicines Agency, or any successor thereof performing substantially the same functions.
1.12. “EU” means the European Union, as its membership may be altered from time to time, or any successor thereto.
1.13. “FDA” means the United States Food and Drug Administration or any successor drug-regulatory entity thereto.
Page 3
1.14. “Field” means all fields.
1.15. “First Commercial Sale” means, with respect to a Licensed Product and country, the first sale on a commercial basis to a Third Party of such Licensed Product in such country after Regulatory Approval has been obtained for such Licensed Product in such country. First Commercial Sale shall expressly exclude: (i) any sale by Kazia to an Affiliate, Sublicensee or Subcontractor (unless the Affiliate, Sublicensee or Subcontractor is the last entity in the distribution chain of the Licensed Product), (ii) distributions of Licensed Product for use in clinical trials, other research and development activities or as samples or for promotional purposes, and (iii) distributions of Licensed Product made at or below cost pursuant to an early access, compassionate use, indigent access or patient assistance program.
1.16. “GAAP” means generally accepted accounting principles applicable to the United States of America, or if applicable, International Financial Reporting Standards, in each case consistently applied.
1.17. “Improvement” means any improvement, enhancement, modification, adaptation, extension, development, mutation, application of and all other technical advances made by or on behalf of a person, whether or not protected by statute.
1.18. “Initiation” means, with respect to a clinical trial, the first dosing of the first subject in such clinical trial.
1.19. “Kazia Personnel” means any employees, consultants and Subcontractors of Kazia and/or any of its Affiliates.
1.20. “Know-How” means any technical, commercial, scientific, regulatory or practical information, proprietary information, know-how, data, trade secrets, processes, methods, protocols, formulas, data, inventions and tangible research property (including, chemical compounds, prototypes and other research tools), whether patentable or otherwise.
1.21. “Licensed Institute Patents” means the patents and patent applications listed in Appendix A (which may be amended from time to time to include additional patents and patent applications covering inventions owned by Institute), (ii) all divisionals, continuations, continuations-in-part, substitutions, confirmations, registrations, validations, additions, extensions, renewals, supplementary protection certificates and restorations of any of the patents or patent applications described in clause (i), (iii) patents issuing from or on any of the patent applications described in clauses (i) or (ii), reissue and/or reexamination patents of the same; and (iv) any counterpart patent or patent application filed in any country that claims to priority to any of the patents or patent applications described in clauses (i), (ii) or (iii).
1.22. “Licensed Institute Rights” means the Licensed Institute Patents and the Licensed Know-How.
Page 4
1.23. “Licensed Know-How” means Know-How that is necessary or useful to practice the Licensed Institute Patents or necessary or useful for the development, manufacture or commercial exploitation of Licensed Products.
1.24. “Licensed Product” means any PI3K Combination the making, use, sale, offer to sell or import of which would otherwise infringe Institute’s rights in a Valid Claim of the Licensed Institute Patents but for the licenses granted herein.
1.25. “Net Sales” means, with respect to any Licensed Product, the gross amount billedby Kazia, its Affiliates and/or its Sublicensees for sale of such Licensed Product to a Third Party less:
| a) | discounts (including cash discounts, trade and quantity discounts), cash and non-cash coupons, price reduction programs, retroactive price reductions, charge-back payments and rebates granted to managed health care organizations or to federal, state and local governments, their agencies, and purchasers or to trade customers or Third Party (“Product Discount”); |
| b) | credits or allowances actually granted upon claims, price adjustments, damaged goods, rejections or returns of such Licensed Product, including such Licensed Product returned in connection with recalls or withdrawals; |
| c) | freight out, postage, shipping, inventory management and insurance charges actually and separately invoiced for delivery of such Licensed Product; |
| d) | supply and manufacturing cost of devices (excluding vials, syringes and hypodermic needles) and diagnostic products approved for use with such Licensed Product and supplied by Kazia, its Affiliates, and/or its Sublicensees; |
| e) | taxes or duties levied on or otherwise imposed on the sale of such Licensed Product, including value-added taxes, or other governmental charges, including that portion of annual fees due under Section 9008 of the United States Patient Protection and Affordable Care Act of 2010 (Pub. L. No. 111-48), only to the extent not paid or reimbursed by the Third Party, or reimbursed or wholly or partially credited by the relevant governments or tax authorities, but in each case excluding taxes based on net income; |
| f) | bad debts relating to sales of Licensed Products that are actually written off by Kazia or its Affiliate or Sublicensee in accordance with GAAP during the applicable calculation period (but which shall be recredited retrospectively if such bad debts are actually wholly or partially recovered at any time after the applicable calculation period); and |
| g) | any other similar customary deductions. |
Notwithstanding the foregoing, amounts billed for the sale of Licensed Products among Kazia and its Affiliates, Subcontractors and Sublicensees shall not be included in the computation of Net Sales hereunder.
Page 5
In the event a Licensed Product is sold as an end-user product consisting of a combination of severable pharmacologically active functional elements or components that are not themselves Licensed Products and that are not being licensed hereunder by Institute (whether coformulated, co-packaged or sold as separate products for a single invoice price), but excluding diagnostic products and devices, then the Net Sales for such Licensed Product shall be calculated by multiplying the Net Sales for such combination in a country by the fraction A/(A+B), where “A” is the invoice price for such Licensed Product sold separately in such country and “B” is the invoice price for the other elements sold separately in such country, in each case in the same calendar year. In the event that such other elements are not sold separately (but such Licensed Product is) in such country in such calendar year, the Net Sales for such Licensed Product shall be calculated by multiplying the Net Sales for such combination by the fraction A/C, where “A” is the invoice price for such Licensed Product, and “C” is the invoice price for the combination, in each case in such country and calendar year. In the case of a combination where such Licensed Product is not sold separately in such country and calendar year, the Parties shall mutually determine in good faith an allocation of Net Sales of such combination attributable to the respective Licensed Product and other elements of such combination, based on the fair market value of such Licensed Product and such elements in the applicable country and calendar year.
Net Sales shall expressly exclude (i) distributions of Licensed Product for use in clinical trials, other research and development activities or as samples or for promotional purposes, and (ii) distributions of Licensed Product made pursuant to an early access, compassionate use, indigent access or patient assistance program
1.26. “Phase 1 Clinical Trial” means a human clinical trial of a Licensed Product on sufficient numbers of volunteers and/or patients that is designed to establish that such Licensed Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trial.
1.27. “Phase 2 Clinical Trial” means a human clinical trial of a Licensed Product, including a separate clinical trial or the second part of a fused “Phase 1/2” trial, where either such separate clinical trial or second part of such fused “Phase 1/2” trial is designed to provide a determination of efficacy or an appropriate dose of such Licensed Product in the target patient population.
1.28. “Phase 3 Clinical Trial ” means a human clinical trial of a Licensed Product on sufficient numbers of patients, including a separate clinical trial or the second part of a fused “Phase 2/3” trial, where either such separate clinical trial or second part of such fused “Phase 2/3” trial is designed to establish that such Licensed Product is efficacious for its intended use, and to define warnings, precautions and adverse reactions that are associated with such Licensed Product in the dosage range to be prescribed, and to support Regulatory Approval of such Licensed Product or label expansion of such Licensed Product. A Phase 3 Clinical Trial shall include a trial intended as a registration trial that will form the basis for obtaining Regulatory Approval, whether or not such Clinical Trial is designated as a Phase 3 Clinical Trial.
1.29. “Regulatory Approval” means any and all full approvals (including full drug approval, supplements, amendments, pre- and post-approvals, but excluding pricing and reimbursement approvals), licenses, registrations or authorizations, of any regulatory authority, national, supra-national (e.g., the European Commission or the Council of the EU), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary for the manufacture, importation, export, storage, promotion, distribution, use or sale of a Licensed Product in a regulatory jurisdiction (including applicable approvals of labelling for a Licensed Product in a jurisdiction and any customs and tax approvals, but excluding any price and reimbursement approval) and including any amendment or supplement of the same.
Page 6
1.30. “Regulatory Authority” means any applicable governmental regulatory authority involved in granting Regulatory Approvals for pharmaceutical products, including the FDA and the EMA.
1.31. “Research Plan” means a research plan agreed to by the Parties and to be conducted under the Collaborative Research Agreement.
1.32. “Royalty Term” has the meaning given in clause 4.4(b).
1.33. The terms “sale,” “sold” and “sell” as used in this Agreement mean sales, leases, licenses, rentals and other modes of distribution or transfer of a product or its beneficial use for valuable consideration. Licensed Products will be considered sold when delivered or billed, whichever occurs first.
1.34. “Semester”, “semestrial” shall mean the timeframe from 1st January to 30th June or from 1st July to 31st December in any calendar year. In any calendar year, the first semester runs from 1st January to 30th June and the second semester runs from 1st July to 31st December.
1.35. “Special Access Scheme” means the scheme established under section 19 of the Therapeutic Goods Act 1989 (Cth) that permits certain Australian registered health practitioners to prescribe an unapproved therapeutic good for an individual patient on a case by case basis.
1.36. “Subcontractor” means a Third Party engaged by Kazia (or one of its Affiliates) or Institute, respectively, to perform contract services on behalf of a Party.
1.37. “Sublicense” shall mean an agreement in which Kazia (i) grants or otherwise transfers any of the rights licensed to Kazia hereunder, (ii) agrees not to assert such rights or to sue, prevent or seek a legal remedy for the practice of same, or (iii) is under an obligation to grant, assign or transfer any such rights or non-assertion, or to forebear from granting or transferring such rights to any other entity, including by means of an option. For the avoidance of doubt, an assignment or transfer of this Agreement is not a Sublicense and is instead governed by Section 11.2.
1.38. “Sublicensee” shall mean any Third Party to which Kazia has granted a Sublicense.
1.39. “Term” has the meaning set forth in Section 7.1.
1.40. “Territory” shall mean all countries in the world.
Page 7
1.41. “Third Party” means any person or entity other than Institute, Kazia, Kazia’s Affiliates, and Institute’s Affiliates.
1.42. “Valid Claim” means: (a) a claim in an issued Licensed Institute Patent that has not: (i) expired or been canceled; (ii) been declared invalid by an unreversed and unappealable or unappealed decision of a court or other appropriate body of competent jurisdiction; (iii) been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or (iv) been abandoned; or (b) a claim under an application for a Licensed Institute Patent that has been pending seven (7) years or less from its earliest priority date and, in any case, which has not been canceled, withdrawn from consideration, finally determined to be unallowable by the applicable governmental authority or court for whatever reason (and from which no appeal is or can be taken), or abandoned.
2. LICENSES
2.1. License Grants.
(a) Grant to Kazia. Subject to the terms and conditions of this Agreement, Institute hereby grants to Kazia and its Affiliates an exclusive, worldwide, sub-licenseable (in accordance with Section 2.2 below), royalty-bearing license in the Field, under the Licensed Institute Patents and the Licensed Know-How, to research, develop, make, have made, use, offer to sell, sell, have sold, keep, export and import Licensed Products.
(b) Grant to Institute. Subject to the terms and conditions of this Agreement, Kazia hereby grants Institute a non-exclusive, royalty-free license (with the right to sublicense to Affiliates, but without the right to sublicense to Third Parties except with prior written consent of Kazia) under the Licensed Institute Patents and the Licensed Know-How to use the Licensed Products for non-commercial research and teaching purposes only, excluding any research or teaching sponsored by a commercial entity, and excluding the right to conduct any research in humans or using materials obtained from a human without Kazia’s prior written consent (not to be unreasonably withheld) and agreement to the applicable terms. Kazia acknowledges that Institute, where appropriate, makes products available through the Special Access Scheme. Institute may only make a Licensed Product available through the Special Access Scheme with Kazia’s prior written consent not to be unreasonably withheld. Institute shall provide data and findings from the Special Access Scheme to Kazia, promptly after they become available to Institute.
2.2. Sublicensing Rights. Kazia shall have the right to sublicense rights licensed under Section 2.1 through multiple tiers to Third Parties, provided that each Sublicense is in writing and is subject to terms and conditions (including those set out in Section 6) that are no less onerous than those set out in this Agreement. Without limiting the generality of the foregoing, Kazia remains solely liable for the performance of its obligations under this Agreement, notwithstanding the grant of any Sublicense.
2.3. Background Intellectual Property. Each Party recognizes that the other Party may, prior to the Effective Date, or pursuant to research conducted after the Effective Date by a person other than the inventors of the Licensed Institute Patents (the “Inventors”) or Kazia Personnel, possess intellectual property conceived of, reduced to practice, first fixed in a tangible medium, discovered or otherwise known or developed outside the scope of this Agreement and which is not subject to the license grants in this Agreement (“Background Intellectual Property”). This Agreement shall not transfer, convey, or assign any rights in Background Intellectual Property or Improvements to Background Intellectual Property from one Party to the other Party, except as may be expressly provided under this Agreement or a separate agreement between the Parties.
Page 8
2.4. No Other Rights. Each Party acknowledges that the rights and licenses granted in this Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party. All rights with respect to any know-how, patent or other intellectual property rights that are not specifically granted herein are reserved to the owner thereof.
3. DILIGENCE
3.1. Diligence.
(a) Kazia shall use Commercially Reasonable Efforts to develop at least one (1) Licensed Product initially in any of the United States, the United Kingdom, Germany, France, Italy or Spain.
(b) Kazia will subsequently determine whether it is commercially reasonable to develop a Licensed Product in additional countries, including Australia, Japan and China, and if so will use Commercially Reasonable Efforts to develop at least one (1) Licensed Product in any applicable of such countries.
3.2. Diligence Milestones. Without limiting Section 3.1, Kazia shall use Commercially Reasonable Efforts to achieve of the following milestones (each a “Diligence Milestone”) by the associated deadline:
| • | First patient dosed in clinical trial sponsored by Kazia Therapeutics within 18 months of the Effective DateFirst patient dosed in a Phase 2 clinical trial sponsored by Kazia Therapeutics within 36 months of the Effective Date |
In the event Kazia does not achieve one of the Diligence Milestones set forth above by its associated deadline, Kazia shall, within sixty (60) days after Institute’s request, provide the Institute with evidence of the existence of a reasonable, good-faith technical justification (e.g., an unanticipated challenge regarding the scale-up of production of a Licensed Product, or the discovery of issues regarding the actual or potential safety, tolerability or efficacy of a Licensed Product that require additional testing, or Institute’s failure to comply with, or delay in conducting, its obligations under the Collaborative Research Agreement), regulatory justification (e.g., a request by a Regulatory Authority for additional testing of a Licensed Product or other feedback from a Regulatory Authority that would alter the development timeline of a Licensed Product) or force majeure justification. Provided that the Institute, acting reasonably, is satisfied that Kazia has provided such evidence and Kazia used Commercially Reasonable Efforts to achieve the applicable Diligence Milestone, Institute and Kazia shall then negotiate in good faith to reasonably adjust the deadline dates for both the currently unachieved Diligence Milestone and all subsequent Diligence Milestones to take into consideration Kazia’s plans to achieve such Diligence Milestones. Should Institute, acting reasonably, conclude that Kazia has not provided satisfactory evidence showing a technical or regulatory justification, then Institute may terminate this Agreement pursuant to Section 7.4(c).
Page 9
3.3. If Kazia has materially breached its Commercially Reasonable Efforts obligations under Section 3.1(a) and fails to cure such breach in accordance with Section 7.3(a), Institute shall have the right to terminate this Agreement in accordance with Section 7.3(a).
3.4. Governance and Diligence Reporting. During the Term, prior to the first Regulatory Approval of a Licensed Product, Kazia will provide Institute when needed formal written reports describing its development program for Licensed Products including progress updates on development, testing, advancement, clinical testing and the anticipated timing thereof, and any technical or regulatory delays, of Licensed Products
3.5. Abandonment. If Kazia decides to abandon, or does in fact abandon, the development or commercialization of all Licensed Products, then Kazia shall forthwith notify Institute in writing and Institute shall have the right to terminate this Agreement immediately by giving notice to Kazia. A suspension of all activities related to the development or commercialization of all Licensed Products shall be deemed to be abandonment for the purposes of this clause 3.5 if Kazia cannot demonstrate, to the reasonable satisfaction of Institute, its good- faith intention to continue such development and commercialization within a period of twelve (12) months. For clarity, it will not be considered a suspension of activities if Kazia or its Affiliate or Sublicensee is exerting Commercially Reasonable Efforts to overcome circumstances outside of its control (such as supply or regulatory issues) that impair its ability to develop or commercialize Licensed Products.
3.6. Institute Assistance. Promptly after the Effective Date, Institute will, at Institute’s cost, deliver to Kazia a complete copy of the Licensed Institute Rights that exist at the Effective Date. If any additional Licensed Institute Rights come into Institute’s Control during the Term, Institute shall promptly provide to Kazia copies of such Licensed Institute Rights. From time to time during the Term, Institute shall assist Kazia with regulatory matters related to Licensed Products as reasonably requested by Kazia.
4. FINANCIAL TERMS
4.1. Subject to receipt of a valid tax invoice from Institute, Kazia shall pay Institute a license fee of one hundred and twenty thousand (USD$120,000) within sixty days (60) business days after the Effective Date. Such payment shall be non-creditable and non-refundable.
4.2. Development Milestone Payments. Development Milestone payments are non- creditable and non-refundable for Licensed Products and shall be payable by Kazia to Institute according to the schedule below. Subject to receipt of a valid tax invoice from Institute, Kazia shall pay Institute such milestone payments within sixty (60) business days subsequent to the first achievement of the applicable milestone event set forth below (each, a “Development Milestone”) for the first Licensed Product, whether achievement is made by Kazia, an Affiliate or Sublicensee.
Page 10
For the avoidance of doubt, when a Development Milestone payment becomes due, any preceding Development Milestones payment(s) which have not yet been paid will also become due at that time. In the event that multiple Development Milestone payments become due at the same time, [***] of the total payment shall become due upon Initiation of the trial and [***] shall become due at the conclusion of the trial. If it is determined that a Phase 3 Clinical Trial is not required, the Initiation of Phase 3 Clinical Trial milestone payment will be due upon the first Regulatory Approval of the first Licensed Product. In addition, if a particular Licensed Product achieves one or more certain Development Milestones below, and is subsequently surpassed as the most advanced Licensed Product by another Licensed Product, such that said other Licensed Product first achieves the subsequent Development Milestone(s), Kazia shall pay Institute for said other Licensed Product for only those Development Milestone(s) that are first achieved with said other Licensed Product. Thus, under no circumstance will a Development Milestone payment be paid by Kazia to Institute more than once, and in no event will the total amount payable under this Section 4.2 exceed USD$[***].
| Development Milestone (for the first Licensed Product) |
|
Fee (in Dollars) | ||
| Initiation of the first Phase 1 Clinical Trial |
|
$[***] | ||
| Initiation of the first Phase 2 Clinical Trial, whichever occurs first |
|
$[***] | ||
| Initiation of the first Phase 3 Clinical Trial |
|
$[***] |
4.3. Approval Milestone Payments. Approval Milestone payments are non-creditable and non-refundable for Licensed Products and shall be payable by Kazia to Institute according to the schedule below. Subject to receipt of a valid tax invoice from Institute, Kazia shall pay Institute such milestone payments within sixty (60) business days subsequent to the first achievement of the applicable milestone event set forth below (each, an “Approval Milestone”) for the first Licensed Product, whether achievement is made by Kazia, an Affiliate or Sublicensee. For the avoidance of doubt, if a particular Licensed Product achieves one or more certain Approval Milestones below, and another Licensed Product first achieves the other Approval Milestone(s), Kazia shall pay Institute for said other Licensed Product for only those Approval Milestone(s) that are first achieved with said other Licensed Product. Thus, under no circumstance will an Approval Milestone payment be paid by Kazia to Institute more than once, and in no event will the total amount payable under this Section 4.3 exceed USD$[***].
| Approval Milestone (for the first Licensed Product) |
|
Fee (in Dollars) | ||
| First Regulatory Approval of a Licensed Product |
|
$[***] |
4.4. Royalties.
Page 11
(a) Subject to Section 4.5 below, during the Royalty Term (defined below), Kazia shall pay to Institute, on a semestrial basis and no later than sixty (60) business days following the end of each Semester, a royalty of [***] on annual worldwide Net Sales of each Licensed Product.
(b) Royalties according to Section 4.4(a) shall be paid on a Licensed Product- by-Licensed Product and country-by-country basis from the First Commercial Sale of such Licensed Product in such country until the later of (i) 10 years after such First Commercial Sale; and (ii) the expiration of the last to expire Valid Claim which would be infringed by the sale of such Licensed Product in such country but for this license (collectively, “Royalty Term”). Upon the expiration of the Royalty Term with respect to a Licensed Product in a country, the license under Section 2.1(a) shall become fully-paid-up, perpetual and irrevocable.
(c) During the Royalty Term for a particular Licensed Product in a particular country, there is no Valid Claim which would be infringed by the sale of that Licensed Product in such country but for this license, the royalty rates under Section 4.4(a) with respect to such Licensed Product and country shall be reduced by [***] unless and until (if ever) a Valid Claim that is infringed by the sale of that Licensed Product in such country exists, at which time, the royalty rates under Section 4.4(a) with respect to such Licensed Product and country shall no longer be reduced during the remainder of the Royalty Term for such Licensed Product in such country (unless a Valid Claim again ceases to exist for such Licensed Product in such country, at which time the reduction set forth in this Section 4.4(c) shall again apply).
(d) If a Third Party sells a Biosimilar Product to a Licensed Product in any country during the Royalty Term for such Licensed Product in that country, and the Net Sales of such Licensed Product in such country during any Semester after or including such sale is decreased from the average Net Sales of such Licensed Product in such country in the two (2) Semesters preceding the first sale of such Biosimilar Product by at least [***], then the royalty rates under Section 4.4(a) with respect to such Licensed Product and country shall be reduced by [***] for such Semester, and such reduced royalty rate shall apply from that time until the end of the Royalty Term for such Licensed Product and country; provided that if both this Section 4.4(d) and Section 4.4(c) apply to any Licensed Product and country, only the reduction under this Section 4.4(d) will apply.
Kazia shall be entitled to offset against royalties owed to Institute on Net Sales [***] of any and all payments made to Third Parties pursuant to agreements entered into in good faith to obtain rights under intellectual property without which a Licensed Product could not be lawfully manufactured, used or sold; provided that such offset shall not exceed [***] of royalties in the aggregate for any Semester, and Kazia shall have the right to carry forward to subsequent Semesters any offsets it does not use on account of such royalty floor.
4.5. Royalty Payments and Reports. Subject to receipt of a valid tax invoice from Institute, all amounts payable to Institute pursuant to Section 4.4 shall be paid in Dollars within sixty (60) business days after the end of the Semester in which the applicable Net Sales were recorded. Each payment of royalties shall be accompanied by a royalty report providing a statement, on a Licensed Product-by-Licensed Product and country-by-country basis, of: (a) the amount of Net Sales of Licensed Products during the applicable Semester, (b) a calculation of the amount of royalty payment due in Dollars on such Net Sales for such Semester, and (c) the amount of withholding taxes, if any, required by Applicable Law to be deducted with respect to such royalties.
Page 12
4.6. Royalty Conditions. Only one (1) royalty will be due with respect to each unit of Licensed Product, regardless of whether this is more than one (1) Valid Claim or Licensed Institute Patent claiming with Licensed Product
4.7. Payment Method. All payments due under this Agreement to Institute shall be made by electronic fund transfer in immediately available funds to an account designated by Institute. All payments hereunder shall be made in Dollars.
4.8. Taxes. Institute will pay any and all taxes levied on account of all payments it receives under this Agreement. If laws or regulations require that taxes be withheld with respect to any payments by Kazia to Institute under this Agreement, Kazia will: (a) deduct those taxes from the remittable payment, (b) pay the taxes to the proper taxing authority, and (c) send evidence of the obligation together with proof of tax payment to Institute on a timely basis following that tax payment. To the extent that amounts are so withheld, such withheld amounts shall be treated for all purposes of this Agreement as having been delivered and paid to Institute. Each Party agrees to cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant agreement or treaty which is in effect. The Parties shall discuss applicable mechanisms for minimizing such taxes to the extent possible in compliance with Applicable Law. In addition, the Parties shall cooperate in accordance with Applicable Law to minimize indirect taxes (such as value added tax, sales tax, consumption tax and other similar taxes) in connection with this Agreement.
4.9. Royalty on Sublicensee Sales. Kazia shall have the responsibility to account for and report sales of any Licensed Product by a Sublicensee on the same basis as if such sales were Net Sales by Kazia. Kazia shall pay to Institute such Sublicensee amounts when due under this Agreement.
4.10. Foreign Exchange. Conversion of sales recorded in local currencies to Dollars shall be performed using the rates published on the U.S. Federal Reserve website with conversion on day of payment of royalties by Kazia to Institute. If a currency is not listed, the mid-market rate (average of bid and ask rates) listed on the website of the U.S. Federal Reserve will be used.
4.11. Records. Kazia shall keep, and shall cause its Affiliates and require its Sublicensees to keep, complete, true and accurate books of accounts and records sufficient to determine and establish the amounts payable under this Agreement. Such books and records shall be kept reasonably accessible and shall be made available for inspection for a three (3) year period in accordance with Section 4.12 below.
Page 13
4.12. Inspection of Kazia Records. Upon reasonable prior notice, Kazia shall permit an independent nationally recognized certified public accounting firm (subject to obligations of confidentiality to Kazia), appointed by Institute and reasonably acceptable to Kazia, to inspect during normal business hours the audited financial records of Kazia to the extent relating to payments to Institute; provided that such inspection shall not occur more often than once per calendar year and shall not involve records previously inspected under this Section 4.12, unless a material error is discovered as part of such inspection in which case Institute shall have the right to conduct a more thorough inspection for the inspected period. If Institute, after inspecting the audited financial records of Kazia discovers material errors, then Kazia shall permit an independent nationally recognized certified public accounting firm (subject to obligations of confidentiality to Kazia), appointed by Institute and reasonably acceptable to Kazia, to inspect during normal business hours the books and records described in Section 4.11; provided that such inspection shall not occur more often than once per calendar year and shall not involve records previously inspected under this Section 4.12, unless a material error is discovered in such inspection in which case Institute shall have the right to conduct an additional audit for the audited period. Any inspection conducted under this Section 4.12 shall be at the expense of Institute, unless such inspection reveals any underpayment of the royalties due hereunder for the audited period by the greater of (a) [***]; or (b) [***] of the aggregate royalties payable for all of the periods subject to the inspection, in which case the reasonable Third Party costs of such inspection for such period shall be borne by Kazia. Any undisputed underpayment shall be paid by Kazia to Institute within ninety (90) days [with interest on the underpayment at the rate specified in Section 4.13 from the date such payment was originally due], and any overpayment refunded within ninety (90) days with interest.
4.13. Late Payments. Any payments or portions thereof due hereunder that are not paid on the date such payments are due under this Agreement shall bear simple interest at a rate equal to [***], in each case calculated on the number of days such payment is delinquent.
4.14. Payments to or Reports by Affiliates. Any payment required under any provision of this Agreement to be made to either Party or any report required to be made by any Party may be made to or by an Affiliate of that Party if designated in writing by that Party as the appropriate recipient or reporting entity.
5. INTELLECTUAL PROPERTY
5.1. Ownership.
Improvements to Licensed Institute Patent and Licensed Know-How. Title to any and all Improvements to Licensed Institute Patents and Licensed Know-How made under this Agreement during the Term by or on behalf of Kazia, and all intellectual property rights covering or relating to such Licensed Institute Patents and Licensed Know-How, shall be in Kazia’s name and solely owned by Kazia, and title to any and all Licensed Institute Patents and Licensed Know-How made under this Agreement during the Term by or on behalf of Institute, and all intellectual property rights covering or relating to such Licensed Institute Patents and Licensed Know-How, shall be in the Institute’s name and solely owned by the Institute. All Improvements to Licensed Institute Patents and Licensed Know-How made under this Agreement by or on behalf of Institute, and all intellectual property rights covering or relating to such Licensed Institute Patents and Licensed Know-How, shall become part of the Licensed Know-How and Licensed Institute Patents, respectively, and included in the grant of rights under Section 2.1.
Page 14
(a) Ownership of intellectual property and inventions arising as a result of the Parties’ activities under a Research Plan are to be set forth within the Collaborative Research Agreement.
5.2. Patent Prosecution.
(a) Subject to Section 5.2(b), on and from the Effective Date, Kazia shall be solely responsible for filing, prosecuting and maintaining the Licensed Institute Patents provided that:
| i. | Institute provides all reasonable cooperation and assistance, including by executing and causing the Inventors to execute all documents as may be necessary or useful in connection with such filing, prosecution and maintenance; |
| ii. | Institute is kept reasonably informed in a timely manner of the status of the patent prosecution; and |
| iii. | Kazia shall take into good faith consideration Institute’s input on any material decision with respect to such patent prosecution. |
(b) If Kazia decides not to pursue a Licensed Institute Patent in a particular jurisdiction, Kazia shall promptly notify Institute in writing of such decision, and Institute may then file, prosecute and maintain such Licensed Institute Patent in that particular country and pay associated costs.
(c) All information exchanged between counsel, the Parties, including Kazia Affiliates where applicable, or the Inventors regarding the Licensed Institute Patents and Licensed Know-How shall be deemed Confidential Information of the Party disclosing the Confidential Information. In addition, the Parties acknowledge and agree that, with regard to such activities, the interests of the Parties as licensor and exclusive licensee are to obtain valid patents that cover the Licensed Products and Licensed Know-How, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege or other legal protection from disclosure concerning the Licensed Institute Patents and Licensed Know-How, including without limitation, privilege under the common interest doctrine and similar or related doctrines.
5.3. Defense and Enforcement Rights for Infringement by Third Parties.
(a) Each Party shall notify the other within fifteen (15) Business Days of becoming aware of any alleged or threatened infringement by a Third Party of any Institute Licensed Patents and Licensed Know-How through the manufacture, use, offer for sale, sale or importation of a Licensed Product or any filing alleging the invalidity, unenforceability or non- infringement of any Institute Licensed Patent and Licensed Know-How or any filing by a Third Party for Regulatory Approval for a product that names a Licensed Product as a reference product (collectively, “Product Infringement”).
(b) Kazia shall have the first right, but not the obligation, to bring and control any legal action in connection with any Product Infringement at its own expense as it reasonably determines appropriate, and Institute shall have the right to be represented in any such action by counsel of its choice at its expense. If Kazia decides not to bring such legal action, or does not bring such legal action within one hundred twenty (120) days of becoming aware of the alleged or threatened infringement, it shall so notify Institute promptly in writing and Institute shall have the right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate after consultation with and written consent from Kazia.
Page 15
(c) At the request and expense of the Party bringing the action, the other Party shall provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required.
(d) In connection with any such proceeding, the Party bringing the action shall not enter into any settlement admitting the invalidity of, or otherwise impairing the other Party’s rights in, the Institute Licensed Patents without the prior written consent of the other Party, which shall not be unreasonably withheld. For the avoidance of doubt, if Institute is the enforcing party, Institute may not grant a license, covenant not to sue or forbearance under any of the Licensed Institute Rights to the alleged infringer(s) as part of settling a Product Infringement as such grants are solely within the control of Kazia in its sole discretion.
(e) Any damages or other recovery from a Product Infringement enforcement action undertaken by either Party pursuant to this Section 5.3 shall:
(i) first be applied towards the reimbursement of the enforcing Party’s costs and expenses associated with such claim (including attorneys’ fees, expert witness fees, court costs and other litigation costs and expenses); and
all remaining amounts resulting from Kazia’s actions under Sections 5.3(b) shall be considered Net Sales, and shall be shared in accordance with Section 4.5 above (without any application of Section 4.4(c) or 4.4(d)), and all amounts resulting from Institute’s actions under Section 5.3(b) shall be allocated [***] to Institute and [***] to Kazia.
6. CONFIDENTIALITY AND PUBLICATION
6.1. Confidential Information. Subject to the remainder of this Section 6, each Party agrees that if it receives Confidential Information from the other Party in connection with this Agreement, the receiving Party will not disclose such Confidential Information to any Third Party, will use it solely to exercise its rights and perform its obligations under this Agreement, and will use reasonable efforts to maintain the confidentiality of such information, including procedures and practices as each would use for its own confidential records. Notwithstanding the foregoing, a receiving Party shall be entitled to make Authorized Disclosures (as defined in Section 6.3 below) of Confidential Information to the extent reasonably necessary, provided that, except for Sections 6.3(a), 6.3(b) and 6.3(e) below, if reasonably possible, the receiving Party provides prior written notice of such disclosure to the disclosing Party and takes or cooperates with the disclosing Party’s efforts to take reasonable and lawful actions to avoid or minimize the degree of such disclosure. In the case of disclosures for regulatory filing or required by law, regulation or regulatory body (including a relevant stock exchange), the disclosing Party shall make reasonable efforts to minimize such disclosure and to obtain confidential treatment for any such information which is disclosed to a government agency, it being understood that the non-disclosing Party shall, where reasonably possible, have the right to review such disclosures to government agencies and request redaction of any information it reasonably deems inappropriate for disclosure, including without limitation, key financial terms not previously disclosed in a public announcement; provided that any such disclosure shall not abrogate future treatment of the information as Confidential Information to the extent that such disclosure does not result in the entrance of such information into the public domain, and provided that the Party making the filing or legally required disclosure shall have the right to determine what it may redact in accordance with Applicable Laws. Notwithstanding the foregoing, Kazia acknowledges that Institute is required under its internal intellectual property policies to share consideration received hereunder with its Inventors (including Inventors that have subsequently left the employ of Institute), and that Institute shall incur no liability for reporting to and paying Inventors in accordance with its internal policies, provided that Institute discloses only what is required under such policies and that such Inventors are bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Section 6.
Page 16
6.2. Term of Confidentiality. A receiving Party’s obligation to keep Confidential Information confidential shall end ten (10) years after the expiration or termination of this Agreement.
6.3. Authorized Disclosure. Authorized disclosures under Section 6.1 (“Authorized Disclosures”) include:
(a) Filing or prosecuting patent applications as permitted under this Agreement;
(b) Regulatory filings by Kazia or any of its Affiliates or Sublicensees;
(c) Prosecuting or defending litigation contemplated under this Agreement;
(d) Complying with applicable governmental laws, regulations and rules of an applicable regulatory body (including a relevant stock exchange); and
(e) Disclosure, on a need-to-know basis, in connection with the performance of this Agreement, or exercise of its rights hereunder or thereunder, (i) in the case of Kazia, to potential collaborators, partners, and actual and potential licensees (including potential co-marketing and co-promotion contractors, research contractors and manufacturing contractors), research collaborators, potential investment bankers, investors, acquirers and lenders, and (ii) in the case of each Party, to its and its Affiliate’s employees, contractors, officers, consultants, professional advisers, auditors or agents, in each case (i) and (ii), each of whom prior to disclosure must be bound by obligations of confidentiality and non-use that are at least as onerous as those set forth in this Section 6.
6.4 Publicity. Any proposed publication, news release or other public announcement by a Party relating to this Agreement or the terms and conditions set forth herein that would disclose information other than that already expressly in the public domain prior to such publication, news release or other public announcement, shall only be made with the prior written consent of the other Party; provided that: (a) Kazia shall have the right to issue any press releases or other public disclosures regarding the status and results of its or its Affiliates’ or Sublicensees’ development and commercialization of Licensed Products without the consent of or prior review by Institute; and (b) Institute may announce the achievement of Development Milestones set forth in Section 4.2 with the consent of Kazia, which shall not be unreasonably withheld. Notwithstanding the previous or anything in this Section 6, nothing herein shall be construed to prevent disclosures required by law, regulation or regulatory body (including a relevant stock exchange); provided that, if possible, in such case the disclosing Party will provide the other Party with as much advance notice of the disclosure as practicable and will consider in good faith such other Party’s input on the proposed disclosure.
Page 17
7. TERM AND TERMINATION
7.1. Term. The term of this Agreement shall commence on the Effective Date and shall continue thereafter until the expiration of the last to expire Royalty Term, unless terminated earlier in accordance with its terms (the “Term”).
7.2. Bankruptcy. If Kazia files a petition in bankruptcy, is the subject of an involuntary bankruptcy proceeding which is not dismissed within sixty (60) days after its commencement, or is placed in the hands of a receiver, assignee, or trustee for the benefit of creditors, whether by the voluntary act of Kazia or otherwise, this Agreement shall automatically terminate, inasmuch as permitted under applicable and prevailing law.
7.3. Institute Termination.
(a) Without limiting any rights to pursue any other remedies at law or in equity, if Kazia fails to make an undisputed payment to Institute in accordance with the terms of this Agreement, or upon Kazia’s other material breach or default of any material term of this Agreement, Institute shall have the right to serve notice upon Kazia (which notice shall include details regarding the nature of the breach and a proposed remedy) of Institute’s intention to terminate the entirety of the rights, privileges and licenses granted hereunder within ninety (90) days from Kazia’s receipt of such notice. If Kazia does not pay all such overdue undisputed amounts to Institute within such ninety (90) day period, or, as applicable, if Kazia fails to reasonably cure such breach or default within such ninety (90) day period, then this Agreement may be immediately terminated by Institute in its entirety or with respect to the applicable country(ies) within a reasonable time period after such ninety (90) day period by written notice to Kazia and all rights in and to the Licensed Institute Rights in the terminated country(ies) will immediately revert to Institute; provided that (i) if such breach or default is not reasonably capable of cure within such ninety (90)-day period, Kazia may submit a reasonable cure plan prior to the end of such ninety (90)-day period, in which case Institute shall not have the right to terminate this Agreement for so long as Kazia is using Diligent Efforts to implement such cure plan, and (ii) if Kazia disputes in good faith the existence or materiality of a breach specified in a notice provided by Institute and Kazia provides Institute notice of such dispute within such ninety (90)-day period, then Institute shall not have the right to terminate this Agreement under this Section 7.3(a) unless and until it is agreed or determined that Kazia has materially breached this Agreement and Kazia fails to cure such breach within ninety (90) days following such decision or agreement, and (iii) if the breach relates to one or more, but not all countries in the Territory, Institute will have the right to terminate this Agreement with respect to such country(ies) only and not this Agreement in its entirety.
Page 18
(b) This Agreement may be immediately terminated by Institute if Kazia challenges the validity of any of the Licensed Institute Patents in a court or government agency of competent jurisdiction, except as a defense to a claim or counter-claim brought by Institute or its Affiliate, and fails to withdraw such challenge within thirty (30) days after written notice from Institute requesting withdrawal.
7.4. Kazia Termination.
(a) Termination for Breach. Without limiting any rights to pursue any other remedies at law or in equity, Kazia shall have the right (but not the obligation) to terminate this Agreement upon written notice to Institute, in the event that Institute has materially breached any of its material obligations and fails to remedy any such breach within ninety (90) days after receiving written notice of such breach from Kazia specifying the nature of such breach. In such notice, Kazia shall, where possible, reasonably identify the actions or conduct that Institute would carry out as an acceptable cure of such breach, provided that any such actions or conduct shall be consistent with the then-current Research Plan (where applicable).
(b) Termination for Convenience. Kazia may terminate this Agreement in its entirety or with respect to one or more country(ies) at any time on one hundred twenty (120) days written notice to Institute.
(c) Termination for Not Achieving Diligence Milestones. Should Institute, acting reasonably, conclude that Kazia has not provided satisfactory evidence showing as contemplated by Section 3.2, then Institute may terminate this Agreement by giving Kazia written notice of termination, which termination will be effective upon the later of the (i) sixty (60) days after the date of such written notice or (ii) the date set forth in the written notice.
(d) Reversion. Upon termination of the entire Agreement under Section 7.2, Section 7.3 or Section 7.4(b), Kazia and its Affiliates, upon the request of Institute and subject to Section 6, shall provide to Institute copies of all material data related to any Licensed Product(s) that have been actively developed or commercialized by Kazia (any such Licensed Product, a “Reverted Institute Product”). Kazia shall also grant Institute a non-exclusive, sublicensable license at fair market value to such data and to all patents and patent applications owned by Kazia and its Affiliates (“Kazia IP”) that are demonstrably referable to a Reverted Institute Product and required for the development or commercialization of a Reverted Institute Product. Institute shall have the right under such license to use such data and Kazia IP in the course of developing any such Reverted Institute Products and otherwise exploiting and commercializing the Licensed Institute Rights, including without limitation, licensing such rights to Third Parties for such purposes. In the event that Institute sublicenses such Kazia IP and related data, Institute shall pay to Kazia a percentage of any consideration received by Institute in connection with such sublicense (“Sublicense Revenue”) according to the following table:
Page 19
| Stage of development of most advanced Reverted Institute Product at the effective date of termination of this Agreement |
Percentage of Sublicense Revenue received by Institute | |
| Prior to commencement of a Phase 1a Clinical Trial | [***] | |
| After commencement of a Phase 1a Clinical Trial but prior to commencement of a Phase 1b/2 Clinical Trial |
[***] | |
| After conclusion of a Phase 1b/2 Clinical Trial but before submission of Regulatory Approval application | [***] | |
| After submission of Regulatory Approval application |
[***] |
7.5. Continued Obligations. Upon termination of this Agreement in whole or in part for any reason, nothing herein shall be construed to release either Party from any obligation that accrued prior to the effective date of such termination. All Confidential Information of the other Party shall be promptly returned or destroyed, at the disclosing Party’s election, provided that a Party may retain one copy of such information solely for archival purposes. After the effective date of such termination of this Agreement, where the Agreement is terminated in accordance with Section 7.2, Section 7.4(a) or Section 7.4(b), Kazia and its Affiliates may, for a period of [six (6) months], sell all Licensed Products, and complete Licensed Products in the process of manufacture at the time of such termination and sell the same, provided that Kazia complies with, and requires its Affiliates and Sublicensees to comply with, all of the terms of this Agreement, and including without limitation: (i) Kazia shall pay to Institute the royalties and other payments as required herein, (ii) insurance required hereunder shall be in effect, and (iii) Kazia shall submit the reports required by Section 4.5 hereof.
7.6. Survival. The provisions of Sections 4.8, 4.11, 4.12, 4.13, 5.1, 6, 7.4, 7.5, 7.6, 7.7, 8, 9, 10.4 and 11 of this Agreement shall survive termination of this Agreement. In the event of a partial termination hereof, those same sections shall survive with respect to the terminated rights, and all of the provisions hereof shall continue in full force and effect with respect to the non-terminated rights.
Page 20
7.7. Effects of Termination on Sublicenses. Upon termination of this Agreement, for any reason, Kazia shall promptly notify its Sublicensees of such termination. Upon notice by Institute of its intent to terminate (or, if notice is not required, upon termination) of this Agreement, Kazia shall no longer have the authority to grant further Sublicenses. Upon request of any Sublicensee, if such Sublicensee is not in default under the Sublicense and if the Sublicense is in conformity with this Agreement, such Sublicensee shall have the right to enter into good faith negotiations to enter into an agreement with Institute, through which such Sublicensee would receive a direct license from Institute and become bound to Institute on substantially the same terms and conditions (including financial terms) obligating Sublicensee as Kazia was bound to Institute under this Agreement (with license terms modifications as are reasonably necessary to accommodate the scope of the sublicense), but only to the extent under terms no less economically favorable to Institute, with respect to the scope of the sublicense, that existed when this Agreement and the Sublicense were in effect, and provided that in no event shall Institute be obligated in any manner that it was not to Kazia hereunder and that the terms of such license agreement shall not impose any representations, warranties, expenses or liabilities on Institute that are not included in this Agreement. If any Sublicensee desires to enter into such a license agreement, it shall be wholly the responsibility of that Sublicensee to notify Institute of such desire within thirty (30) days after the effective date of termination of this Agreement, and such Sublicensee will be deemed to have a direct license from Institute during the period between the effective date of termination of this Agreement and the earliest of (a) thirty (30) days thereafter if such Sublicensee fails to notify Institute of such desire by such date, (b) one hundred eighty days (180) thereafter or (c) Institute’s and Sublicensee’s entry into such agreement. If Institute and the Sublicensee for any reason do not enter into such a license within one hundred eighty (180) days after the effective date of termination of the Agreement, the Sublicense and all rights granted thereunder shall automatically terminate.
8. DISPUTES AND GOVERNING LAW
8.1. Governing Law. This Agreement is subject to and shall be construed and enforced in accordance with the laws of the Queensland, Australia.
8.2. Informal Dispute Resolution. The Parties acknowledge and agree that they have entered into this Agreement with the expectation of a long-term, mutually beneficial relationship. However, in the event of a dispute arising hereunder, the Parties agree to resolve such disputes in the following manner:
(c) in the event of any dispute, controversy or claim arising out of, relating to or in connection with this Agreement, the Parties shall try to settle such differences amicably between themselves first, by referring the disputed matter to the Party’s respective Executive Officers. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and, within twenty (20) business days after such notice (or such longer period agreed by the Parties), such Executive Officers shall meet for attempted resolution by good faith negotiations. If such Executive Officers are unable to resolve such dispute within thirty (30) business days (or such longer period agreed by the Parties) of their first meeting for such negotiations, either Party may seek to have such dispute resolved in accordance with Section 8.3. For purposes of this Section 8.2, “Executive Officers” means: (a) in the case of Institute, the Director and Chief Executive Officer and the Chief Operating Officer of Institute or a direct report of same; and (b) in the case of Kazia, the Chief Executive Officer or a direct report of same.
Page 21
8.3. Formal Dispute Resolution.
(c) Patent-related disputes. All claims, disputes, or controversies that are not resolved under Section 8.2 concerning the inventorship relating to any inventions, or the validity, construction, or scope of any of the Licensed Institute Patents, and all related claims or counterclaims will be brought exclusively in a court or other governmental authority of competent jurisdiction in the jurisdiction in which the patent rights arose.
(d) Other disputes. All other claims, disputes or controversies arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination, that are not resolved under Section 8.2 shall be referred to and finally and exclusively resolved by arbitration administered by the International Chamber of Commerce (“ICC”) in accordance with the Rules of Arbitration of the ICC for the time being in force, which rules are deemed to be incorporated by reference in this clause. The tribunal shall consist of three arbitrator(s) selected in accordance with such rules. The language of the arbitration shall be English. Each Party shall bear its own attorneys’ fees and associated costs and expenses regarding any arbitration. The existence and content of the arbitral proceedings and any rulings or awards shall be kept confidential by the Parties and members of the arbitral tribunal except (i) to the extent that disclosure may be required of a Party to fulfill a legal duty (including disclosure obligations imposed by law, regulation or regulatory body (including a relevant stock exchange)), protect or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings before a state court or other judicial authority, (ii) with the consent of both Parties, (iii) where needed for the preparation or presentation of a claim or defense in this arbitration, (iv) where such information is already in the public domain other than as a result of a breach of this clause, or (v) by order of the arbitral tribunal upon application of a Party.
(e) Urgent Relief. Nothing in this Section 8 prevents a Party from seeking any lawfully available equitable relief, including urgent injunctive relief or restraining order, in a court having jurisdiction.
9. INDEMNIFICATION LIABILITY AND INSURANCE
9.1. Liability
Except for indemnification obligations in Section 9.2(b) and except for damages available for breach of Section 6, the liability of the Institute in connection with this Agreement shall be limited to the lower of: (i) the total amount paid by Kazia under this Agreement at the time the liability arises; or (ii) [***] dollars.
9.2. Indemnification.
| (a) | Kazia agrees to indemnify Institute and its officers, trustees, Inventors, personnel, agents, employees, and each of their respective successors and assigns (collectively, “Institute Indemnitees”), against any damages, losses, expenses, or liabilities resulting from any and all claims by a Third Party to the extent arising from: (i) the exercise of any rights licensed hereunder by Kazia, its parents, assigns, successors, affiliates (including Affiliates), customers, or other transferees; and (ii) the manufacture, use, sale, marketing or import of Licensed Products by or on behalf of Kazia or its Affiliates, except, in each case (i) and (ii), to the extent arising from an Institute Indemnitee’s negligence, recklessness or willful misconduct or Institute’s breach of this Agreement. Prior to commencing any human clinical trials hereunder, Kazia shall obtain and maintain product liability and general liability insurance, through its self-insurance program or otherwise, and shall require each of its authorized Affiliates to have such insurance. Reasonable written evidence of the existence and sufficiency of such insurance shall be provided to Institute annually or upon Institute’s reasonable request. |
Page 22
(b) Institute agrees to indemnify Kazia and its Affiliates, and Sublicensees and their respective officers, directors, personnel, agents, employees, and each of their respective successors and assigns (collectively, “Kazia Indemnitees”), against any damages, losses, expenses, or liabilities resulting from any and all claims by a Third Party to the extent arising from: (i) Institute’s negligence, recklessness or willful misconduct; or (ii) the manufacture, use, sale, marketing or import of Reverted Institute Products by or on behalf of Institute or its Affiliates or licensees, except, in each case (i) and (ii), to the extent arising from Kazia’s negligence or willful misconduct or Kazia’s breach of this Agreement.
(c) A Party seeking indemnification shall promptly notify the indemnifying Party of any legal action or claim that may result in liability to such indemnifying Party under this Section 9. The indemnifying Party shall be permitted to assume control over the investigation, defense and settlement of the action or claim, provided however, that the indemnifying Party shall not enter into any settlement that contains an admission of liability or restriction on behalf of or affecting any of the respective Institute Indemnitees or Kazia Indemnitees, or that does not contain an unconditional release of any indemnitees, without the written consent of the other Party, such consent not to be unreasonably withheld. The indemnified Party shall reasonably cooperate, and cause its indemnitees to cooperate, with the indemnifying Party in its investigation, defense and settlement of such action or claim. The indemnifying Party shall have no liability in respect of any settlement entered into by an indemnitee without the prior written consent of the indemnifying party.
10. REPRESENTATIONS, WARRANTIES, AND DISCLAIMERS
10.1. Kazia Representations and Warranties. Kazia represents and warrants that:
(a) as of the Effective Date, Kazia has the right, power and authority to enter into this Agreement;
(b) as of the Effective Date, there are no court orders, injunctions, decrees or settlements pertaining to Kazia or its Affiliates that restrict Kazia’s or its affiliates’ collaboration, development, or commercialization activities as contemplated under this Agreement; and
(c) its duly authorized representative has executed this Agreement on behalf of Kazia.
(d) It will not enter a sublicense under Section 2.2 with a party whose organizational purpose could be viewed as fundamentally incompatible with a not-for-profit medical research organization and therefore , in the reasonable view of Institute, could cause reputational harm to the Institute., for example, organisations which are actively dealing in, or are promoting the use of, tobacco, arms, alcohol, illicit drugs; or which are supporting countries, other organisations or individuals which are sanctioned by the United Nations or the US Government; or which do not adhere to legally required standards of anti-discrimination, anti-bribery, environmental protection, animal welfare, safety.
Page 23
10.2. Institute Representations and Warranties. Institute represents and warrants and, as applicable, covenants that:
(a) as of the Effective Date, Institute has the right, power and authority to enter into this Agreement;
(b) as of the Effective Date, there are no court orders, injunctions, decrees or settlements pertaining to Institute that restrict Institute’s activities as contemplated under this Agreement;
(c) its duly authorized representatives have executed this Agreement on behalf of Institute;
(d) as at the Effective Date and on each day during the Term, Institute is the sole owner of the Licensed Know-How and the Licensed Institute Patents, free and clear of all liens and encumbrances, and has the right to grant the licenses as purported to be granted herein;
(e) as at the Effective Date and on each day during the Term, Institute has not entered, and shall not enter, into any agreement with any Third Party that is in conflict with the rights granted to Kazia under this Agreement, and has not taken and shall not take any action that would in any way prevent it from granting the rights granted to Kazia under this Agreement, or that would otherwise materially conflict with or adversely affect Kazia’s rights under this Agreement;
(f) as at the Effective Date and on each day during the Term, it has not received any written notices of, and is not otherwise aware of, challenges to any of the Licensed Institute Patents, including oppositions, claims, interferences or reexaminations;
(g) as at the Effective Date, it is not aware of an infringement or misappropriation of any Licensed Institute Rights by any Third party;
(h) as at the Effective Date, the Licensed Institute Rights are the complete and accurate scope of rights required by Kazia to research, develop, make, have made, use, offer to sell, sell, have sold, keep, and import Licensed Products; and
(i) as at the Effective Date and on each day during the Term, to the best of Institute’s knowledge, Institute and its Affiliates have complied with all Applicable Laws in connection with the Licensed Institute Rights.
Page 24
10.3. Intellectual Property Disclaimers Except as otherwise expressly provided in Section 10.2, all rights licensed by Institute hereunder are licensed “as is” and without any representation or warranty with respect to possible infringement of third party rights. Nothing in this Agreement shall be construed as: (i) a warranty or representation by Institute as to the validity, enforceability, or scope of any Licensed Institute Rights, (ii) a warranty or representation that anything made, used, imported, developed, promoted, offered for sale, sold, or otherwise disposed of under any license granted in this Agreement does not or will not infringe patents, trade secrets or other proprietary rights of third parties, (iii) a representation or warranty of operability or that development of a commercial product is possible, (iv) an obligation to bring or prosecute actions or suits against third parties for infringement, (v) conferring the right to use in advertising, publicity or otherwise any trademark, trade name, or names, or any contraction, abbreviation, simulation or adaptation thereof of Kazia or Institute, (vi) conferring by implication, estoppel or otherwise any license or rights under any patents of Institute other than the Licensed Institute Patents, and (vii) any other representations or warranties, either express or implied, unless specified in this Agreement. Except as expressly provided herein, the furnishing of Confidential Information shall not be interpreted to convey any grant of rights, titles, interests, options or licenses to the receiving Party under any of the Licensed Institute Rights or any such Confidential Information.
10.4. Additional Disclaimers. TO THE EXTENT PERMITTED BY LAW, EACH PARTY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY STATED IN THIS SECTION 10, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE LICENSED INSTITUTE RIGHTS OR ANY LICENSED PRODUCTS OR RESEARCH ACTIVITIES, AND INCLUDING WARRANTIES WITH RESPECT TO THE SCOPE, VALIDITY OR ENFORCEABILITY OF ANY OF THE LICENSED INSTITUTE RIGHTS, THAT ANY PATENT WILL ISSUE BASED UPON ANY OF THE PENDING APPLICATIONS COMPRISING SAME, OR THAT THE USE OF ANY OF THE LICENSED INSTITUTE RIGHTS WILL NOT INFRINGE OR OTHERWISE VIOLATE INTELLECTUAL PROPERTY RIGHTS OF ANOTHER PARTY. EXCEPT AS SET FORTH IN SECTION 9.1 WITH RESPECT TO THE PARTIES’ INDEMNIFICATION OBLIGATIONS AND EXCEPT FOR DAMAGES AVAILABLE FOR BREACH OF SECTION 6, NEITHER PARTY OR THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES OR AFFILIATES (IN THE CASE OF KAZIA) SHALL BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR INDIRECT DAMAGES OF ANY KIND ARISING OUT OF OR RELATED TO THIS AGREEMENT, INCLUDING LOST PROFITS, WHETHER GROUNDED IN TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, CONTRACT OR OTHERWISE.
Page 25
11. MISCELLANEOUS PROVISIONS
11.1. Notices. Any report, notice, or other communication given under this Agreement (except for correspondence necessary in the Patent Prosecution Section hereinabove) shall be in writing and addressed to the Parties as follows (or at such other addresses as the Parties may notify each other in writing) (“Specified Contact Details”):
Institute:
Business Development
QIMR Berghofer Medical Research Institute
Locked Bag 2000, Royal Brisbane Hospital, QLD 4029 Australia
Attention: GM Business Development
Email: [***]
Phone: [***]
Kazia:
Kazia Therapeutics Limited
Attention: John Friend, MD
Email: [***]
Phone: [***]
Such report, notice or other communication given under this Agreement will be deemed to be given by the sender and received by the addressee:
(a) if delivered in person, when it is left at the recipient’s address set out in the Specified Contact Details;
(b) if posted to the recipient’s address set out in the Specified Contact Details, at 9.00 am on the fifth business day after the date of posting to the addressee whether delivered or not; or
(c) if sent by email, 2 hours after the time the email is sent to the recipient’s email address set out in the Specified Contact Details, as recorded on the sender’s email system, unless the sender receives, within that time period, an automatic notification (other than an out of office message) indicating that the email has not been delivered,
but if the delivery or receipt is on a day which is not a business day or is after 4.00 pm (addressee’s time), it is deemed to have been received at 9.00 am on the next business day. In this clause, “business day” means a day that is not a Saturday, Sunday or public holiday and on which banks are open for business generally, in the place to which the communication is posted, sent or delivered.
Page 26
11.2. Assignment. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective permitted assigns and successors in interest. Kazia may transfer this Agreement (by assignment or otherwise) and/or the rights acquired by it hereunder to an Affiliate or a Third Party, but, in the case of an assignment to a Third Party, only with the written consent of the Institute, not to be unreasonably withheld, except that Kazia may assign this Agreement without such consent to a Third Party successor in connection with a merger, acquisition or sale of all or substantially all of its assets to which this Agreement relates unless the organizational purpose of the Third Party could be viewed as fundamentally incompatible with a not-for-profit medical research organization and therefore, in the reasonable view of Institute, the assignment could cause reputational harm to the Institute, for example, organisations which are actively dealing in, or are promoting the use of, tobacco, arms, alcohol, illicit drugs; or which are supporting countries, other organisations or individuals which are sanctioned by the United Nations or the US Government; or which do not adhere to legally required standards of anti- discrimination, anti-bribery, environmental protection, animal welfare, safety. In the event of a request to assign to a Third Party that requires Institute’s consent, Kazia shall provide Institute with written evidence that such transferee has resources and commitment sufficient to fulfill the obligations it is assuming thereunder, at the time of the assignment, and if the Third Party transferee shall not have agreed in writing to be bound by the terms and conditions of this Agreement, Institute shall have the right to immediately terminate this Agreement. For avoidance of doubt, any transfer of this Agreement or Kazia’s rights or duties hereunder by Kazia, in whole or in part, to an Affiliate does not require advance written consent of Institute. Institute shall not assign this Agreement without Kazia’s prior written consent. Any purported assignment in violation of the foregoing shall be null and void.
11.3. Non-Use of Names. Neither Party shall use the name, logo, likeness, trademarks or image of the other Party for publicity, advertising, marketing, or endorsement without the specific prior written consent of an authorized representative of the other Party as to each such use. Notwithstanding the foregoing and Section 5, Kazia may state without such prior consent that it licensed from Institute one or more of the patents and/or patent applications comprising the Licensed Institute Patents.
11.4. Severability. Should any provision of this Agreement be determined to be unenforceable or otherwise unlawful, then such provision shall be without effect, as if such provision had not been included herein, and the remaining terms of this Agreement shall survive. In such instance, the Parties shall promptly meet to agree upon further terms which shall, within the confines of the law, most substantially satisfy the intention of the Parties as reflected by the ineffective provision. If such agreement between the Parties is not reached within thirty (30) days (or longer such period agreed by the parties) of the date such provision is determined to be unenforceable or otherwise unlawful, the Parties agree to submit such matter for resolution in accordance with the dispute resolution provisions hereinabove.
11.5. Headings. The Section and other headings contained in this Agreement are for reference purposes only, and shall not in any way affect the meaning or interpretation of this Agreement. The singular shall include the plural and vice versa. “Including” shall mean “including but not limited to.”
11.6. Benefit and Waiver. This Agreement is binding upon and shall inure to the benefit of the Parties, their representatives, successors and permitted assigns. No failure or successive failures on the part of the Parties to enforce any provisions of this Agreement, and no waiver or successive waivers on either Party’s part of any condition of this Agreement, shall operate as a discharge of such provision or condition, or render the same invalid, or impair the right of such Party to enforce same in the event of any subsequent breach or breaches by the other Party.
Page 27
11.7. Entire Agreement. The Parties agree that this Agreement sets forth the entire agreement and understanding of the Parties as to the subject matter hereof, and supersedes any and all prior written and oral agreements, understandings, promises or offers, including without limitation any term sheet which preceded its drafting and the Confidentiality Agreement, which is hereby terminated, and shall not be subject to any change or modification except by the execution of a written instrument subscribed to by the Parties hereto and explicitly referencing this Agreement and specifying that it is the Parties’ intent to modify the terms or conditions set forth herein. The Parties acknowledge that invoices, purchase orders or other mechanisms for administering any payment or other obligation set forth herein shall not contain terms and conditions separate from, in addition to, or in conflict with this Agreement, and that any such terms, if present, shall be void and without effect, and shall not be enforceable by any Party. Each Party acknowledges that it was represented by counsel of its choosing in the drafting and negotiation of this Agreement, and agrees that neither Party will be deemed to be the drafter of such Agreement for any purpose, including its construction or interpretation.
11.8. Independent Contractors. Each Party shall act as an independent contractor and shall not be construed for any purpose as the agent, employee, servant, or representative of the other Party. Accordingly, the employee(s) of one Party shall not be considered to be employee(s) of the other Party, and neither Party shall enter into any contract or research agreement with a third party which purports to obligate or bind the other Party.
11.9. No Third Party Beneficiaries. This Agreement is intended solely for the benefit of the Parties and shall not be deemed to create any rights in any other person or entity, except that (a) Kazia’s Affiliates are intended third party beneficiaries on the obligations of Institute under this Agreement and (b) Sublicensees are intended third party beneficiaries of the rights and obligations under Section 7.7.
11.10. Counterparts. This Agreement may be executed in counterparts, each of which shall be treated as an original, but which together shall constitute a single instrument.
11.11. Force Majeure. No Party shall be liable for any delay or failure of performance to the extent such delay or failure is caused by circumstances beyond its reasonable control and that by the exercise of due diligence it is unable to prevent, provided that the Party claiming excuse uses its Commercially Reasonable Efforts to overcome the same.
11.12. Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
Page 28
IN WITNESS WHEREOF, the Parties hereto have agreed and accepted the terms and conditions of, and have duly executed this Agreement to be made effective as of the Effective Date.
| KAZIA THERAPEUTICS LIMITED |
THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH | |||||
| By: /s/ John E. Friend II |
By: /s/ Fabienne Mackay | |||||
|
|
John E. Friend II |
|
Fabienne Mackay | |||
| Title: |
Chief Executive Officer |
Title: |
Director and CEO | |||
| By: |
|
|||||
| [ ] |
||||||
| Title: |
||||||
Page 29
Appendix A
LICENSED INSTITUTE PATENTS
|
Patent Application No. |
Filing Date |
Jurisdiction |
Title | |||
| No. [***] |
21 November 2022 |
Australia Patent Application |
PI3K COMBINATION | |||
|
No. [***] |
13 February 2024 |
Australia Patent Application |
[***] |
Page 30